Xiaofeng Ye Sells 6,000 Shares of Adlai Nortye (NASDAQ:ANL) Stock

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) CFO Xiaofeng Ye sold 6,000 shares of the business’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $13.98, for a total value of $83,880.00. Following the completion of the sale, the chief financial officer directly owned 153,424 shares in the company, valued at $2,144,867.52. This trade represents a 3.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xiaofeng Ye also recently made the following trade(s):

• On Wednesday, August 26th, Xiaofeng Ye sold 5,667 shares of Adlai Nortye stock. The shares were sold at an average price of $14.25, for a total value of $80,754.75.

Adlai Nortye Price Performance

Shares of ANL traded up $1.31 during trading hours on Wednesday, hitting $15.05. The company had a trading volume of 147,795 shares, compared to its average volume of 397,755. The firm has a fifty day moving average price of $11.91 and a 200-day moving average price of $11.13. The company has a debt-to-equity ratio of 0.04, a current ratio of 9.55 and a quick ratio of 0.65. Adlai Nortye Ltd. Sponsored ADR has a 52-week low of $0.88 and a 52-week high of $17.25.

Analysts Set New Price Targets

Several brokerages have issued reports on ANL. Oppenheimer assumed coverage on shares of Adlai Nortye in a report on Thursday, May 28th. They issued an “outperform” rating and a $32.00 target price for the company. Cantor Fitzgerald assumed coverage on shares of Adlai Nortye in a report on Monday, June 22nd. They set an “overweight” rating on the stock. Wall Street Zen raised shares of Adlai Nortye from a “hold” rating to a “buy” rating in a research report on Saturday. JonesTrading initiated coverage on shares of Adlai Nortye in a research report on Thursday, May 14th. They set a “buy” rating and a $22.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adlai Nortye in a research report on Tuesday, July 14th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Adlai Nortye presently has an average rating of “Moderate Buy” and a consensus target price of $24.25.

Institutional Investors Weigh In On Adlai Nortye

Large investors have recently bought and sold shares of the business. SmartHarvest Portfolios LLC lifted its stake in Adlai Nortye by 8.5% during the 1st quarter. SmartHarvest Portfolios LLC now owns 16,367 shares of the company’s stock valued at $113,000 after acquiring an additional 1,279 shares during the period. Renaissance Technologies LLC bought a new stake in shares of Adlai Nortye in the first quarter worth approximately $457,000. Seven Fleet Capital Management LP bought a new stake in shares of Adlai Nortye in the second quarter worth approximately $1,302,000. ADAR1 Capital Management LLC purchased a new position in shares of Adlai Nortye during the first quarter valued at approximately $816,000. Finally, Affinity Asset Advisors LLC purchased a new position in shares of Adlai Nortye during the first quarter valued at approximately $1,140,000. 35.21% of the stock is currently owned by institutional investors.

About Adlai Nortye

Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.